CODX Share Price Performance
US$1.11
-9.49 (-89.53%)
63.0% undervalued intrinsic discount
US$3.00
Fair Value
Price US$1.11
AnalystConsensusTarget US$3.00
AnalystHighTarget US$10.00
AnalystLowTarget US$1.00
Fair ValueUS$3.00
Share Pricen/a
Co-Diagnostics, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
CODX Community Narratives
AN
Fair Value
·Fair Value US$3 63.0% undervalued intrinsic discount
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$10 88.9% undervalued intrinsic discount
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$1 11.0% overvalued intrinsic discount
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Co-Diagnostics
63.0% undervalued intrinsic discount
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
View narrativeAN
Updated 18 Oct 2025
Co-Diagnostics
11.0% overvalued intrinsic discount
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
View narrativeAN
Published 18 Aug 2025
Co-Diagnostics
88.9% undervalued intrinsic discount
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
View narrativeAN
Published 17 Aug 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Fair Value: US$3 63.0% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
Fair Value: US$1 11.0% overvalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
Fair Value: US$10 88.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Co-Diagnostics, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -7.53
- 43.48%
- -6,523.05%
- 0%
About CODX
- Founded
- 2013
- Employees
- 115
- CEO
- WebsiteView website
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
